Literature DB >> 6086891

Adenosine inhibition of catecholamine-induced increase in force of contraction in guinea-pig atrial and ventricular heart preparations. Evidence against a cyclic AMP- and cyclic GMP-dependent effect.

M Böhm, R Brückner, I Hackbarth, B Haubitz, R Linhart, W Meyer, B Schmidt, W Schmitz, H Scholz.   

Abstract

The antagonism between adenosine and isoprenaline on force of contraction, cyclic AMP (cAMP) and cyclic GMP (cGMP) content, adenylate cyclase activity and transmembrane action potential in isolated electrically driven atrial and ventricular muscle preparations from guinea-pig hearts was investigated. In atrial preparations adenosine added 5 min after isoprenaline decreased force of contraction. Adenosine abolished completely the positive inotropic effect of isoprenaline. Similarly, adenosine prevented the positive inotropic effect of isoprenaline when both substances were added simultaneously. In ventricular preparations adenosine also decreased the isoprenaline-induced increase in force of contraction. The effect was much smaller than it was in the atria. Adenosine reduced the isoprenaline-induced increase in force of contraction only by about 60%. Adenosine did not at all influence the positive inotropic effect of isoprenaline when both substances were added simultaneously. In both preparations the isoprenaline-induced increase in cAMP content of the intact contracting preparations was not diminished by adenosine. cGMP content remained unchanged too. Adenosine inhibited adenylate cyclase activity in broken cell preparations from both tissues. In atrial preparations the decrease in force of contraction of adenosine in the presence of isoprenaline was accompanied by a shortening of the action potential duration. In ventricular preparations adenosine failed to shorten the action potential. In conclusion, the effects of adenosine to inhibit the stimulatory action of isoprenaline on myocardial force of contraction are not due to changes in the cAMP and/or cGMP content. Instead, adenosine may inhibit a step beyond an increased cAMP level, e.g., may exert an inhibition of protein kinases. However, in the atria, but not in the ventricles, an additional direct effect of adenosine on transmembrane ion currents, most likely an increase in potassium conductance, probably is of even greater importance.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6086891

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  40 in total

1.  Effects of 1,3-dipropyl-8-cyclopentylxanthine (DPCPX), a highly selective adenosine receptor antagonist, on force of contraction in guinea-pig atrial and ventricular cardiac preparations.

Authors:  H von der Leyen; W Schmitz; H Scholz; J Scholz; M J Lohse; U Schwabe
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989-08       Impact factor: 3.000

2.  Pharmacological characterization of A1 adenosine receptors in isolated rat ventricular myocytes.

Authors:  D Martens; M J Lohse; B Rauch; U Schwabe
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1987-09       Impact factor: 3.000

3.  Role of guanine nucleotide-binding protein in the regulation by adenosine of cardiac potassium conductance and force of contraction. Evaluation with pertussis toxin.

Authors:  M Böhm; R Brückner; J Neumann; W Schmitz; H Scholz; J Starbatty
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1986-04       Impact factor: 3.000

4.  Involvement of purine compounds in the inotropic action of milrinone.

Authors:  P Dorigo; R M Gaion; I Maragno
Journal:  Cardiovasc Drugs Ther       Date:  1990-04       Impact factor: 3.727

5.  Mechanism underlying the reduced positive inotropic effects of the phosphodiesterase III inhibitors pimobendan, adibendan and saterinone in failing as compared to nonfailing human cardiac muscle preparations.

Authors:  H von der Leyen; U Mende; W Meyer; J Neumann; M Nose; W Schmitz; H Scholz; J Starbatty; B Stein; H Wenzlaff
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1991-07       Impact factor: 3.000

6.  Characterization of the K(+)-channel-coupled adenosine receptor in guinea pig atria.

Authors:  H Tawfik-Schlieper; K N Klotz; V A Kreye; U Schwabe
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989-12       Impact factor: 3.000

7.  Regulation of force and intracellular calcium transients by cyclic AMP generated by forskolin, MDL 17,043 and isoprenaline, and its modulation by muscarinic receptor agents: a novel mechanism for accentuated antagonism.

Authors:  M Endoh
Journal:  Basic Res Cardiol       Date:  1989       Impact factor: 17.165

8.  Effects of adenosine analogues on contractile response and cAMP content in guinea-pig isolated ventricular myocytes.

Authors:  J Neumann; W Schmitz; H Scholz; B Stein
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989-12       Impact factor: 3.000

9.  Studies of the nucleoside transporter inhibitor, draflazine, in the human myocardium.

Authors:  M Böhm; C Weinhold; R H Schwinger; J Müller-Ehmsen; D Böhm; H Reichenspurner; B Reichart; E Erdmann
Journal:  Br J Pharmacol       Date:  1994-05       Impact factor: 8.739

10.  Electrophysiological actions of adenosine and aminophylline in spontaneously beating and voltage-clamped rabbit sino-atrial node preparations.

Authors:  H Satoh
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-02       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.